Filing Flows › UroGen Pharma (URGN) › Q2 2026 › vs Q2 2025
UroGen Pharma (URGN) Q2 2026 vs Q2 2025 (year over year)
UroGen Pharma's revenue rose $48.2M (+199%) from $24.2M in Q2 2025 to $72.5M in Q2 2026. The biggest changes: Zusduri +$50.4M (—); Jelmyto −$2.2M (-9%).
UroGen Pharma, Q2 2026: revenue $72.5M (+199% year over year), operating margin 0.2%, net loss $14.4M, operating cash flow −$33.0M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Zusduri | $50.4M | $0 | $50.4M | — |
| Jelmyto | $22.0M | $24.2M | −$2.2M | -9% |
| Revenue | $72.5M | $24.2M | $48.2M | +199% |
| Net loss | $14.4M | $49.9M | −$35.6M | -71% |
| Costs & expenses | $86.8M | $74.2M | $12.7M | +17% |
| Operating costs | $72.3M | $65.7M | $6.7M | +10% |
| Interest & other, net | $8.8M | $7.5M | $1.4M | +18% |
| Income tax | $5.6M | $1.0M | $4.6M | +455% |
| Cost of revenue | $6.6M | $3.5M | $3.0M | +85% |
| Research & development | $17.3M | $18.9M | −$1.6M | -8% |
| SG&A | $48.4M | $43.2M | $5.2M | +12% |
| Operating cash sources | $38.4M | $42.7M | −$4.2M | -10% |
| Depreciation & amortization | $100K | $100K | $0 | 0% |
| Share-based compensation | $5.3M | $2.7M | $2.6M | +95% |
| Cash used in operations | $33.0M | $39.8M | −$6.8M | -17% |
| Net loss absorbed | $14.4M | $49.9M | −$35.6M | -71% |
| Working capital & other | $24.1M | −$7.3M | $31.4M | — |
Questions
How much did UroGen Pharma's revenue grow year over year in Q2 2026?
UroGen Pharma's revenue rose $48.2M (+199%) from $24.2M in Q2 2025 to $72.5M in Q2 2026.
What drove UroGen Pharma's revenue change in Q2 2026?
Zusduri +$50.4M (—); Jelmyto −$2.2M (-9%).